Type-1 Diabetes
Conditions
Brief summary
Closed-loop strategy is composed of three components: glucose sensor to read glucose levels, insulin pump to infuse insulin and a dosing mathematical algorithm to decide on the required insulin dosage based on the sensor's readings. A dual-hormone closed-loop system would regulate glucose levels through the infusion of two hormones: insulin and glucagon. The main goal of this project is to assess whether a dual-hormone closed-loop strategy would alleviate the burden of carbohydrate counting from patients with type 1 diabetes (T1D) without a significant degradation in post-meal glucose control. Each patient will be admitted twice to a clinical research facility. In one visit, patients will eat a morning meal accompanied with a matching insulin bolus (depending on the carbohydrate content of the meal) and glucose levels will be subsequently regulated using dual-hormone closed-loop system. In the other visit, patients will eat the same meal but will inject only a partial insulin bolus (not depending on carbohydrate content of the meal) and the remaining needed insulin will be delivered based on glucose sensor excursions as part of closed-loop operation. If post-meal glucose levels were indifferent between the two visits, then this would suggest that carbohydrate counting may not be necessary during closed-loop operation as the closed-loop system will give any remaining insulin needed to cover the glucose absorbed from the meal. Twelve subjects will be enrolled in this study.
Interventions
DEVICEDual Hormone closed-loop system
The closed-loop system is composed of three components: continuous glucose system, insulin infusion pumps that infuses insulin and glucagon and a control algorithm that decides on the infusion rates based on sensor readings.
Sponsors
McGill University
Montreal Children's Hospital of the MUHC
Institut de Recherches Cliniques de Montreal
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* Males and females ≥ 18 and ≤ 65 years of old. * Clinical diagnosis of type 1 diabetes for at least one year. The diagnosis of type 1 diabetes is based on the investigator's judgment and medical history (e.g. history of acido-ketosis, etc.); C peptide level and antibody determinations are not needed. * The subject will have been on insulin pump therapy for at least 3 months. * Last (less than 3 months) HbA1c ≤ 12%.
Exclusion criteria
* Clinically significant nephropathy, neuropathy (especially clinically significant gastroparesis) or retinopathy as judged by the investigator. * Recent (\< 3 months) acute macrovascular event e.g. acute coronary syndrome or cardiac surgery. * Pregnancy. * Severe hypoglycemic episode within two weeks of screening. • Medication likely to affect with the interpretation of the results: Prandase, Victoza, Byetta and Symlin * Known or suspected allergy to the trial products or meal contents. * Other serious medical illness likely to interfere with study participation or with the ability to complete the trial by the judgment of the investigator. * Failure to comply with team's recommendations (e.g. not willing to eat snack, not willing to change pump parameters, etc). * Unreliable carbohydrate counting * Problems with venous access
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incremental area under the curve of plasma glucose concentration as compared to pre-meal glucose value of the postprandial glucose excursions | 0-300min |
Secondary
| Measure | Time frame |
|---|---|
| Mean plasma glucose concentration. | — |
| Total insulin delivery | — |
| Total glucagon delivery | — |
| Percentage of postprandial time of plasma glucose concentrations spent in the high range (above 10.0 mmol/l). | 0-300 min |
| Postprandial peak and incremental postprandial peak of plasma glucose concentration | — |
| Percentage of time of plasma glucose concentrations spent in target range. Target range is defined to be between 4.0 and 10.0 mmol/l for 150 minutes postmeal and between 4.0 and 8.0 mmol/l afterwards | — |
| Percentage of postprandial time of plasma glucose concentrations spent in the low range (below 4.0mmol/l) | 0-300min |
| Plasma glucose concentration and incremental plasma glucose concentration at 2 hours postmeal | — |
Countries
Canada
Outcome results
None listed